NineSigma Capitalizes on Growth of Open Innovation; Reports a Record Year for 2007
February 21, 2008 09:33 ET
|
NineSigma, Inc.
CLEVELAND, OH--(Marketwire - February 21, 2008) - As a result of the growing demand for open
innovation solutions, NineSigma
today reported record revenues for 2007. The company's success was...
Pharmaceutical and Biopharmaceutical Companies Need to Reassess the Way They Operate, According to Tufts Center for the Study of Drug Development
February 05, 2008 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - February 5, 2008) - How drug developers organize their companies
affects operational and financial performance, according to new research
findings presented to a panel of...
Tufts Center for the Study of Drug Development to Launch R&D Senior Management Roundtable Series Feb. 28
January 28, 2008 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 28, 2008) - The Tufts
Center for the Study of Drug Development today announced that it is
expanding its R&D Senior Management Roundtable, from a single...
Growing Complexity of Clinical Trials Increases Burden on Investigators and Volunteers, According to Tufts Center for the Study of Drug Development
January 15, 2008 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 15, 2008) - More complex clinical trial protocols are
demanding more of investigative site personnel and study volunteers,
leading to longer clinical trials and...
New Approaches to Drug Development Will Drive Drug Company Success, According to Tufts Center for the Study of Drug Development
January 03, 2008 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 3, 2008) - Drug companies, under significant pressure to
develop new prescription medicines faster and at lower cost, are more
likely to succeed if they change the...
Notable Gender, Racial Disparities Exist Among U.S. Clinical Investigators, According to the Tufts Center for the Study of Drug Development
November 13, 2007 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - November 13, 2007) - Although the overwhelming majority of physicians
in the United States have high interest in participating in clinical
research studies, the actual...
Despite More Cancer Drugs in R&D, Overall U.S. Approval Rate Is Eight Percent, According to the Tufts Center for the Study of Drug Development
September 05, 2007 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - September 5, 2007) - Although the number of new cancer drugs entering
clinical development more than doubled between the early 1990s and
mid-2000s, only eight percent of...
Follow-on Drugs Are Key to World Health Organization, According to the Tufts Center for the Study of Drug Development
July 10, 2007 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - July 10, 2007) - Follow-on drugs play a central role in World
Health Organization (WHO) drug policy, suggesting that initiatives which
impede follow-on drug research and...